康妇消炎栓联合抗生素治疗盆腔炎性疾病的系统评价和Meta分析

目的评价康妇消炎栓联合抗生素治疗盆腔炎性疾病的疗效及安全性。方法检索国内外数据库,根据纳入与排除标准筛选文献、提取资料,并评价纳入研究的方法学质量,采用RevMan5.3软件进行Meta分析。结果最终纳入25项篇RCT(n=4102),纳入研究方法学质量均较低。Meta分析显示表明康妇消炎栓联合抗生素治疗盆腔炎性疾病临床治愈率高于单用抗生素组疗法(RR=1.43,95%CI1.31~1.56);腹痛缓解时间(SMD=-1.65,95%CI-2.27,-1.04)及抗生素使用疗程(SMD=-1.60,95%CI-2.22,-0.58)均短于单用抗生素组,联合用药组复发率(RR=0.22,95%CI0.12~0.41)及不良反应总发生率(RR=0.53,95%CI0.38~0.74)较单用抗生素组低。结论康妇消炎栓作为辅助疗法联合抗生素治疗盆腔炎性疾病可提高盆腔炎性疾病临床治愈率,并能缩短症状缓解时间及抗生素使用时间,降低不良反应发生率。由于纳入研究方法学质量偏低,该结论需更多高质量临床研究加以验证。

Efficacy and safety of Kangfuxiaoyan suppository combined with antibiotics for pelvic inflammatory disease: A systematic review and Meta analysis

Objective To determine the effection and safety of Kangfuxiaoyan suppository combined with antibiotics for pelvic inflammatory disease. Methods Seven databases were searched, and the literatures was selected according to the inclusion and exclusion criteted. Revman 5.3 software was used for Meta analysis. Results Twenty-five RCTs (n=4102) were included. Meta analysis showed that the clinical cure rate of Kangfuxiaoyan suppository combined with antibiotics for pelvic inflammatory disease was higher than that of antibiotic therapy alone (RR=1.43, 95%CI 1.31~1.56). The abdominal pain relief time (SMD=-1.65, 95%CI -2.27, -1.04, and the antibiotic treatment duratimen (SMD=-1.60, 95%CI -2.22, -0.58) were shorter than the control group. The relapse rate of the combination group (RR=0.22, 95%CI 0.12~0.4 and the total incidence of adverse reactions (RR=0.53, 95%CI 0.38-0.74) were lower than that of the antibiooup alone. Conclusion Kangfuxiaoyan suppository combined with antibiotics for the treatment of pelvic inflammatory disease could improve the clinical cure rate, shorten the time of symptom relief,and reduce the incidence of adverse reactions. Due to the low quality of the included research methodology, this conclusion needs to be validated by more high-quality randomized controlled